These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 36746879

  • 1. Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma.
    Fukushima M, Tajima K, Sasaki R, Nakao Y, Takahashi K, Ozawa E, Miuma S, Kato T, Miyaaki H, Nakao K.
    Clin J Gastroenterol; 2023 Jun; 16(3):402-406. PubMed ID: 36746879
    [Abstract] [Full Text] [Related]

  • 2. Fatal fulminant hemolysis-associated pulmonary embolism in mixed-type autoimmune hemolytic anemia: A case report.
    Imataki O, Iseki K, Uchida S, Uemura M, Kadowaki N.
    Medicine (Baltimore); 2020 Feb; 99(6):e18984. PubMed ID: 32028408
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
    Hidaka Y, Tomita M, Desaki R, Hamanoue M, Takao S, Kirishima M, Ohtsuka T.
    World J Surg Oncol; 2022 Jul 12; 20(1):228. PubMed ID: 35831894
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
    Fukushima T, Morimoto M, Kobayashi S, Ueno M, Uojima H, Hidaka H, Kusano C, Chuma M, Numata K, Tsuruya K, Arase Y, Kagawa T, Hattori N, Ikeda H, Watanabe T, Tanaka K, Maeda S.
    Oncologist; 2023 Jul 05; 28(7):e526-e533. PubMed ID: 37023703
    [Abstract] [Full Text] [Related]

  • 9. Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Furuichi N, Naganuma A, Kaburagi T, Suzuki Y, Hoshino T, Shibusawa N, Horiguchi S, Hatanaka T, Kakizaki S, Uraoka T.
    Clin J Gastroenterol; 2023 Jun 05; 16(3):422-431. PubMed ID: 36821067
    [Abstract] [Full Text] [Related]

  • 10. Autoimmune thrombocytopenic purpura, autoimmune hemolytic anemia and gastric cancer appeared in a patient with myasthenia gravis.
    Wakata N, Kiyozuka T, Konno S, Nakazora H, Nomoto N, Sugimoto H, Nemoto H.
    Intern Med; 2006 Jun 05; 45(7):479-81. PubMed ID: 16679706
    [Abstract] [Full Text] [Related]

  • 11. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S, Yano Y, Fujishima Y, Ishida J, Kido M, Kuramitsu K, Yamamoto A, Goto T, Yanagimoto H, Toyama H, Ueda Y, Kodama Y, Fukumoto T.
    Anticancer Res; 2022 Mar 05; 42(3):1403-1412. PubMed ID: 35220233
    [Abstract] [Full Text] [Related]

  • 12. Complications of Evans' syndrome in an infant with hereditary spherocytosis: a case report.
    Yoshida H, Ishida H, Yoshihara T, Oyamada T, Kuwana M, Imamura T, Morimoto A.
    J Hematol Oncol; 2009 Sep 10; 2():40. PubMed ID: 19740448
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment.
    Takakusagi S, Tanaka H, Naganuma A, Kakizaki S, Shibuya K, Ohno T, Takagi H, Uraoka T.
    Clin J Gastroenterol; 2023 Jun 10; 16(3):407-415. PubMed ID: 36750524
    [Abstract] [Full Text] [Related]

  • 16. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Furusawa A, Naganuma A, Suzuki Y, Hoshino T, Yasuoka H, Tamura Y, Naruse H, Hatanaka T, Kakizaki S.
    Clin J Gastroenterol; 2022 Apr 10; 15(2):451-459. PubMed ID: 35179703
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
    Komatsu S, Fujishima Y, Kido M, Kuramitsu K, Goto T, Yanagimoto H, Toyama H, Fukumoto T.
    BMC Gastroenterol; 2021 Dec 15; 21(1):470. PubMed ID: 34911458
    [Abstract] [Full Text] [Related]

  • 19. A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy.
    Hagiwara S, Komeda Y, Nishida N, Yoshida A, Kudo M.
    Cancer Rep (Hoboken); 2022 Nov 15; 5(11):e1721. PubMed ID: 36224043
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.